Coherus Oncology, Inc. (CHRS)

Coherus Oncology Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	82.92	88.88	125.99	102.89	63.55	417.2
Short-Term Investments	22.38	83.25	-	14.86	128.13	-
Cash & Short-Term Investments	105.31	172.13	125.99	117.75	191.68	417.2
Cash Growth	-55.69%	36.62%	7.00%	-38.57%	-54.05%	-22.91%
Accounts Receivable	13.88	17.82	111.32	260.52	109.96	123.02
Other Receivables	0.37	0.6	11.01	-	-	-
Receivables	14.25	18.42	122.33	260.52	109.96	123.02
Inventory	5.67	3.17	4.21	62.61	38.79	37.64
Prepaid Expenses	8.56	12.99	16.88	34.76	40.8	24.46
Other Current Assets	-	-	72.18	-	-	-
Total Current Assets	133.79	206.71	341.58	475.63	381.23	602.32
Property, Plant & Equipment	0.87	4.3	7.09	11.03	14.44	16.01
Goodwill	-	-	-	0.94	0.94	0.9
Other Intangible Assets	44.99	46.24	53.65	70.73	4.99	2.66
Other Long-Term Assets	11.54	1.1	46.21	71.27	79.24	57.44
Total Assets	191.18	258.34	448.53	629.6	480.85	679.33

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	13.17	9.92	28.46	35.22	11.53	16.16
Accrued Expenses	37.74	63.58	227.04	291.11	122.85	145.68
Current Portion of Long-Term Debt	-	-	1.15	-	-	-
Current Portion of Leases	1.95	1.83	1.69	2.15	4.32	3.49
Other Current Liabilities	22.66	65.07	24.65	3.3	-	-
Total Current Liabilities	75.51	140.39	282.98	331.77	138.69	165.33
Long-Term Debt	51.77	51.08	292.52	473.37	471.06	408.28
Long-Term Leases	0.46	1.46	3.29	5.33	5.05	7.25
Long-Term Deferred Tax Liabilities	1.1	1.1	1.1	1.1	-	-
Other Long-Term Liabilities	1.5	3.31	0.63	11.46	3.47	0.75
Total Liabilities	130.35	197.33	580.52	823.03	618.27	581.61

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.02	0.01	0.01	0.01	0.01	0.01
Additional Paid-In Capital	1,503	1,444	1,419	1,386	1,204	1,148
Retained Earnings	-1,442	-1,383	-1,551	-1,580	-1,342	-1,050
Comprehensive Income & Other	-0.28	-0.2	-0.28	-0.25	-0.25	-0.27
Total Common Equity	60.84	61.01	-131.99	-193.43	-137.42	97.73
Shareholders' Equity	60.84	61.01	-131.99	-193.43	-137.42	97.73
Total Liabilities & Equity	191.18	258.34	448.53	629.6	480.85	679.33

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	54.18	54.36	298.65	480.84	480.42	419.02
Net Cash (Debt)	51.13	117.76	-172.66	-363.09	-288.74	-1.83
Net Cash Growth	-72.14%	-	-	-	-	-
Net Cash Per Share	0.39	1.01	-1.51	-3.86	-3.72	-0.02
Filing Date Shares Outstanding	154.5	149.89	115.9	112.71	79.61	77.28
Total Common Shares Outstanding	154.47	121.15	115.61	112.22	78.85	76.93
Working Capital	58.28	66.32	58.6	143.86	242.54	437
Book Value Per Share	0.39	0.50	-1.14	-1.72	-1.74	1.27
Tangible Book Value	15.85	14.78	-185.64	-265.1	-143.35	94.16
Tangible Book Value Per Share	0.10	0.12	-1.61	-2.36	-1.82	1.22
Machinery	-	10.82	18.07	17.73	17.39	16.04
Construction In Progress	-	-	-	-	0.7	0.39
Leasehold Improvements	-	5.76	5.75	5.75	6.2	5.94

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: May 11, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 30, 2026

Data Sources Report a data error